JPRN-UMIN000018484招募中2 期
A phase II study to evaluate the effectiveness of S-1 + Cetuximab for patients with advanced/recurrent colon cancer who cannot undergo intensive therapy - S-1 and Cetuximab Colon Cancer trial ( SACC trial )
HO HOKKAIDO CANCER CENTER Division of Gastroenterology0 个研究点目标入组 57 人开始时间: 2015年8月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 57
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 65years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) History of severe allergy 2) Active synchronous or metachronous malignancy 3) Severe infectious disease 4) Severe complications (interstitial lung disease or pulmonary fibrosis, heart failure, kidney failure, hepatic failure, uncontrolable diabetes, Jaundice) 5) Massive pleural effusion or ascites 6) Wattery diarrhea 7) Prior treatment of cetuximab or L-OHP or TS-1 8) Patients who is receiving Flucytosine 9) Symptomatic brain metastasis 10) Pregnant or lactating women or women of childbearing potential 11) Severe mental disorders 12) Systemic administration of steroid 13) Severe renal failure, or urinary protein (more than 2+). 14) Prior radiotherapy for primary and metastases leision. 15) History of allergy for L-OHP and other platinating agent 16) Sensory alteration or paresthesia interfering with function. 17) Any other cases who are regarded as inadequate for study enrollment by the investigator.
研究者
相似试验
招募中
2 期
Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin*s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy.Aggressive B-cell NHL10025320lymphomaNL-OMON36830HOVO60
进行中（未招募）
不适用
Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-cell lymphoma with CNS localisation - HOVON 80 NHrelapsed B cell lymphomaMedDRA version: 8.1Level: LLTClassification code 10029547Term: Non-Hodgkin's lymphomaEUCTR2006-002141-37-NLHOVON foundation35
进行中（未招募）
不适用
Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy.Aggressive B-cell NHLMedDRA version: 14.1Level: PTClassification code 10003902Term: B-cell lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10003903Term: B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-007083-28-NLHOVON foundation60
进行中（未招募）
不适用
A Pilot Phase II Study for the evaluation of efficacy and tolerability of Gammaidroxybutyrate (ALCOVER) administered by oral route as add on treatmant in patients affected by DYT 11 Myoclonic Dystonia. - NDEUCTR2006-001039-23-ITISTITUTO NEUROLOGICO CARLO BESTA
进行中（未招募）
1 期
VAC071: A study to assess efficacy of the ChAd63/MVA PvDBP vaccinesPlasmodium vivax malariaMedDRA version: 20.0Level: LLTClassification code 10047665Term: Vivax malaria (benign tertian)System Organ Class: 100000004862EUCTR2019-000643-27-GBniversity of Oxford / Clinical Trials and Research Governance19